CORAL GABLES, FL / ACCESSWIRE / January 17, 2019 / The future of healthcare stocks, and the medical sector industry as a whole, is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC: PHGRF) (CSE: PHGI), LM Funding America Inc., (NASDAQ: LMFA), CorMedix Inc (NYSE: CRMD), and ContraFect Corp (NASDAQ: CFRX) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) has seen impressive gains during the month of January, as the cannabis sector has garnered notoriety and seen a significant increase in public support. Recently, Premier has focused its efforts on investing in opportunities that combine healthcare and cannabis to develop a business model that targets several key issues areas for consumers.
In recent news, Premier Health Group (OTC: PHGRF) (CSE: PHGI) announced that as part of its international expansion strategy, it has entered into a strategic partnership with China'a 360 Health, a healthcare subsidiary of 360 Security Technology. The parent company, 360 Security Technology, is a leading online service company in China with a market capitalization of over $20 billion USD as of January 16, 2019 . As part of the collaboration, Premier and 360 Health will implement an infrastructure whereby Premier will be providing second opinion services by connecting 360 Health's patients in China with doctors in Canada both remotely and in person. Premier will also assist with General Practitioner training virtually and onsite through medical seminars.
In response to this announcement, Dr. Essam Hamza, CEO of Premier, said, ''We are very excited to be working with 360 Health as China continues to adopt a Family Practice primary care model and look forward to helping them establish themselves as a leader in primary care. This partnership represents an excellent opportunity for Premier to tap into the fastest growing telemedicine market globally.''
For More Information On Premier Health Group, Click Here
LM Funding America Inc (LMFA), a tech-based specialty finance company, today announced that, in a strategic investment meant to increase company involvement in healthcare, it has completed the acquisition of all of the outstanding stock of IIU, Inc, pursuant to definitive agreements formalizing the Letter of Intent the Company entered into on December 20, 2018. The transaction was approved by the Board of Directors on January 15, 2019 following a legal and business due diligence review, according to the announcement.
Following the announcement of the agreement, LM Funding's CEO Bruce Rodgers said, ''We are excited to complete this acquisition, which is expected to be accretive to earnings in 2019, as we merge IIU operations into the Company. We anticipate evaluating additional growth investments that are accretive to earnings.''
For More Information On LM Funding America, Inc., Click Here
CorMedix Inc (CRMD), a biopharmaceutical company largely focused on developing and commercializing treatment options for the prevention and treatment of countless diseases, announced earlier this month that it had closed and drawn a previously announced $7.5 million, senior secured convertible debt financing with its largest shareholder.
In a press release regarding the matter, Khoso Baluch, CorMedix CEO, commented, ''We are pleased to have met our objective to complete this transaction by December 31, 2018. This financing significantly improves our financial condition as we commence what we believe will be the final steps in our Neutrolin® development plan. Our next objective is to report the top-line results of the LOCK-IT-100 study, following a database lock and unblinding, which are expected to occur in the near future.''
For More Information on CorMedix, Inc., Click Here
ContraFect Corp (CFRX), a clinical-stage biotechnology company purposed with developing treatment via the use of protein and antibody therapeutics, today announced that the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the Company $2.3 million in necessary funding over a two-year period.
Following the announcement of the award, Cara Casino, Chief Medical Officer of ContraFect, said, ''We are pleased to have been awarded this additional funding from CARB-X. This follows our recent announcement of positive topline data from the Phase 2 trial of our lead lysin candidate exebacase, or CF-301, for the treatment of Staph aureus bacteraemia, including endocarditis, which establishes clinical proof of concept for lysins as therapeutic agents.''
For More Information On ContraFect Corp, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/17/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.
CONTACT:
SOURCE: Stock Price